Clinical Research Directory
Browse clinical research sites, groups, and studies.
Residual Exacerbations With Mepolizumab
Sponsor: Laval University
Summary
This will be a two-year prospective study to characterize the nature of the remaining asthma exacerbations in patients treated with mepolizumab. Participants will be assessed every six months from pre- until two years of treatment in addition to whenever they experience an exacerbation of asthma during the study period. During these visits, various clinical, physiological and inflammatory outcomes will be assessed.
Official title: Type and Mechanisms of Residual Asthma Exacerbations in Patients Treated With Mepolizumab
Key Details
Gender
All
Age Range
18 Years - 90 Years
Study Type
OBSERVATIONAL
Enrollment
60
Start Date
2021-07-06
Completion Date
2028-01
Last Updated
2025-02-10
Healthy Volunteers
No
Conditions
Interventions
Mepolizumab
100 mg subcutaneous injections every four weeks
Locations (1)
Institut universitaire de cardiologie et de pneumologie de Québec
Québec, Quebec, Canada